Prothena Q3 net loss narrows to $36.5 mln

Reuters

Nov 07, 2025

Prothena Q3 net loss narrows to $36.5 mln

Overview

Prothena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mln
Company highlighted Phase 3 trials for prasinezumab and coramitug
Prothena to hold EGM for potential share redemption program in 2026

Outlook

Prothena expects 2025 net cash use of $170 to $178 mln
Company anticipates ending 2025 with $298 mln in cash
Prothena plans share redemption program vote in Nov 2025

Result Drivers

R&D EXPENSES - Decrease in R&D expenses attributed to lower clinical trial and personnel costs
COLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trial
CASH POSITION - Strong cash position supports pipeline advancement

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$2.42 mln
Q3 Net Income		-$36.54 mln
Q3 Operating Expenses		$42.66 mln
Q3 Pretax Profit		-$36.91 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Prothena Corporation PLC is $14.50, about 29.2% above its November 5 closing price of $10.27

Press Release: ID:nBw7Py0DGa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581721045"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581721045\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581721045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581721045","market":"nz","top_or_hot":-1,"title":"Prothena Q3 net loss narrows to $36.5 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Prothena Q3 net loss narrows to $36.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Prothena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mln</p></li><li><p>Company highlighted Phase 3 trials for prasinezumab and coramitug</p></li><li><p>Prothena to hold EGM for potential share redemption program in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Prothena expects 2025 net cash use of $170 to $178 mln</p></li><li><p>Company anticipates ending 2025 with $298 mln in cash</p></li><li><p>Prothena plans share redemption program vote in Nov 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses attributed to lower clinical trial and personnel costs</p></li><li><p>COLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trial</p></li><li><p>CASH POSITION - Strong cash position supports pipeline advancement</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$2.42 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$36.54 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.66 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$36.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Prothena Corporation <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $14.50, about 29.2% above its November 5 closing price of $10.27</p></li></ul><p>Press Release: <span>ID:nBw7Py0DGa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena Q3 net loss narrows to $36.5 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena Q3 net loss narrows to $36.5 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Prothena Q3 net loss narrows to $36.5 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Prothena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mln</p></li><li><p>Company highlighted Phase 3 trials for prasinezumab and coramitug</p></li><li><p>Prothena to hold EGM for potential share redemption program in 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Prothena expects 2025 net cash use of $170 to $178 mln</p></li><li><p>Company anticipates ending 2025 with $298 mln in cash</p></li><li><p>Prothena plans share redemption program vote in Nov 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Decrease in R&amp;D expenses attributed to lower clinical trial and personnel costs</p></li><li><p>COLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trial</p></li><li><p>CASH POSITION - Strong cash position supports pipeline advancement</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$2.42 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$36.54 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.66 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$36.91 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Prothena Corporation <a href=\"https://laohu8.com/S/PLC\">PLC</a> is $14.50, about 29.2% above its November 5 closing price of $10.27</p></li></ul><p>Press Release: <span>ID:nBw7Py0DGa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1571399168.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1JR:1","article_id":"2581721045","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581721045","pubTimestamp":1762466333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prothena Q3 net loss narrows to $36.5 mlnOverviewProthena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mlnCompany highlighted Phase 3 trials for prasinezumab and coramitu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4534":"瑞士信贷持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BMY":"施贵宝","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","PRTA":"Prothena Corporation plc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4588":"碎股","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0237698245.USD":"富达环球地产基金A"},"translate_title":"Prothena第三季度净亏损收窄至3650万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9,"BMY":0.9},"content_text":"Prothena Q3 net loss narrows to $36.5 mlnOverviewProthena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mlnCompany highlighted Phase 3 trials for prasinezumab and coramitugProthena to hold EGM for potential share redemption program in 2026OutlookProthena expects 2025 net cash use of $170 to $178 mlnCompany anticipates ending 2025 with $298 mln in cashProthena plans share redemption program vote in Nov 2025Result DriversR&D EXPENSES - Decrease in R&D expenses attributed to lower clinical trial and personnel costsCOLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trialCASH POSITION - Strong cash position supports pipeline advancementKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$2.42 mlnQ3 Net Income-$36.54 mlnQ3 Operating Expenses$42.66 mlnQ3 Pretax Profit-$36.91 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Prothena Corporation PLC is $14.50, about 29.2% above its November 5 closing price of $10.27Press Release: ID:nBw7Py0DGaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}